within Pharmacolibrary.Drugs.ATC.V;

model V03AF09
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.9999999999999996e-05,
    adminDuration  = 600,
    adminMass      = 3900 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AF09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Glucarpidase is an enzyme (carboxypeptidase G2) used to rapidly lower toxic plasma levels of methotrexate in patients with delayed methotrexate clearance due to renal impairment. It hydrolyzes methotrexate into inactive metabolites. The drug is approved for use in the United States for this specific indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with impaired renal function who received glucarpidase 50 Units/kg intravenously as a single dose.</p><h4>References</h4><ol><li><p>Phillips, M, et al., &amp; Ward, S (2008). Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. <i>Journal of clinical pharmacology</i> 48(3) 279–284. DOI:<a href=&quot;https://doi.org/10.1177/0091270007311571&quot;>10.1177/0091270007311571</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18192538/&quot;>https://pubmed.ncbi.nlm.nih.gov/18192538</a></p></li><li><p>Fukaya, Y, et al., &amp; Kawamoto, H (2022). A Dose-Confirmation Phase 1 Study to Evaluate the Safety and Pharmacology of Glucarpidase in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 11(3) 364–371. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1010&quot;>10.1002/cpdd.1010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34435467/&quot;>https://pubmed.ncbi.nlm.nih.gov/34435467</a></p></li><li><p>Scott, JR, et al., &amp; Crews, KR (2015). Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. <i>Pediatric blood &amp; cancer</i> 62(9) 1518–1522. DOI:<a href=&quot;https://doi.org/10.1002/pbc.25395&quot;>10.1002/pbc.25395</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25631103/&quot;>https://pubmed.ncbi.nlm.nih.gov/25631103</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AF09;
